Brown Rudnick advises Lupin on strategic licensing agreement with InspiRX
PUBLISHED ON: 02/25/2015
Brown Rudnick represented transnational pharmaceutical company Lupin on its strategic licensing agreement with InspiRX Inc. The agreement grants Lupin exclusive rights to promote, distribute and market the InspiraChamber® Anti-Static Valved Holding Chamber in the United States. Rob Funsten, Co-Chair of Brown Rudnick's Global Life Sciences Group, was the lead attorney on the transaction.
To learn more about this deal, please read the following press release: